BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23169915)

  • 1. More movements in neuroimmunology.
    Lim M; Vincent A
    Brain; 2012 Nov; 135(Pt 11):3201-2. PubMed ID: 23169915
    [No Abstract]   [Full Text] [Related]  

  • 2. Reopening the case for anti-basal ganglia antibodies (ABGAs): identification of dopamine-2 receptor antibodies associated with movement disorders.
    Balint B; Bhatia K
    Mov Disord; 2013 Jun; 28(6):733. PubMed ID: 23801559
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibody mediated encephalitis.
    Ingram G; Robertson NP
    J Neurol; 2013 Apr; 260(4):1187-90. PubMed ID: 23515700
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders.
    Dale RC; Merheb V; Pillai S; Wang D; Cantrill L; Murphy TK; Ben-Pazi H; Varadkar S; Aumann TD; Horne MK; Church AJ; Fath T; Brilot F
    Brain; 2012 Nov; 135(Pt 11):3453-68. PubMed ID: 23065479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Autoantibodies Associated with Autoimmune Basal Ganglia Disorders].
    Sakuma H
    Brain Nerve; 2018 Apr; 70(4):363-369. PubMed ID: 29632284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-Methyl-D-aspartate receptor or dopamine-2 receptor.
    Mohammad SS; Sinclair K; Pillai S; Merheb V; Aumann TD; Gill D; Dale RC; Brilot F
    Mov Disord; 2014 Jan; 29(1):117-22. PubMed ID: 24115338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-basal ganglia antibody].
    Hayashi M
    Brain Nerve; 2013 Apr; 65(4):377-84. PubMed ID: 23568985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders.
    Tanaka S; Matsunaga H; Kimura M; Tatsumi Ki; Hidaka Y; Takano T; Uema T; Takeda M; Amino N
    J Neuroimmunol; 2003 Aug; 141(1-2):155-64. PubMed ID: 12965267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class.
    Castillo-Gómez E; Oliveira B; Tapken D; Bertrand S; Klein-Schmidt C; Pan H; Zafeiriou P; Steiner J; Jurek B; Trippe R; Prüss H; Zimmermann WH; Bertrand D; Ehrenreich H; Hollmann M
    Mol Psychiatry; 2017 Dec; 22(12):1776-1784. PubMed ID: 27502473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias.
    Egan MF; Hurd Y; Hyde TM; Weinberger DR; Wyatt RJ; Kleinman JE
    Synapse; 1994 Nov; 18(3):178-89. PubMed ID: 7531873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies in movement and psychiatric disorders: updated concepts in detection methods, pathogenicity, and CNS entry.
    Sinmaz N; Amatoury M; Merheb V; Ramanathan S; Dale RC; Brilot F
    Ann N Y Acad Sci; 2015 Sep; 1351():22-38. PubMed ID: 26083906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chlorides in the cerebrospinal fluid in psychiatric diseases].
    Pogády J; Hudáková G
    Cesk Psychiatr; 1965 Jun; 61(3):156-62. PubMed ID: 5837217
    [No Abstract]   [Full Text] [Related]  

  • 13. Balancing the basal ganglia circuitry: a possible new role for dopamine D2 receptors in health and disease.
    Cazorla M; Kang UJ; Kellendonk C
    Mov Disord; 2015 Jun; 30(7):895-903. PubMed ID: 26018615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacology of tardive dyskinesias.
    Klawans HL
    Am J Psychiatry; 1973 Jan; 130(1):82-6. PubMed ID: 4264755
    [No Abstract]   [Full Text] [Related]  

  • 15. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
    Saur HB; Bartenstein P; Schober O; Oberwittler C; Lerch H; Masur H
    Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine-2 receptor extracellular N-terminus regulates receptor surface availability and is the target of human pathogenic antibodies from children with movement and psychiatric disorders.
    Sinmaz N; Tea F; Pilli D; Zou A; Amatoury M; Nguyen T; Merheb V; Ramanathan S; Cooper ST; Dale RC; Brilot F
    Acta Neuropathol Commun; 2016 Dec; 4(1):126. PubMed ID: 27908295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to surface dopamine-2 receptor and N-methyl-D-aspartate receptor in the first episode of acute psychosis in children.
    Pathmanandavel K; Starling J; Merheb V; Ramanathan S; Sinmaz N; Dale RC; Brilot F
    Biol Psychiatry; 2015 Mar; 77(6):537-47. PubMed ID: 25168608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dopamine D2 receptor: new surprises from an old friend.
    Bonci A; Hopf FW
    Neuron; 2005 Aug; 47(3):335-8. PubMed ID: 16055058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune focal encephalitis shows marked hypermetabolism on positron emission tomography.
    Sekigawa M; Okumura A; Niijima S; Hayashi M; Tanaka K; Shimizu T
    J Pediatr; 2010 Jan; 156(1):158-60. PubMed ID: 20006770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.